Resmetirom Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 80 mg ,100 mg

Reference Brands: Rezdiffra (USA)

Category: Gastrointestinal Drugs

Product Description:

Resmetirom, marketed under the brand name Rezdiffra, is an innovative oral medication developed for the treatment of non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). It is specifically indicated for adult patients with moderate to advanced liver fibrosis, corresponding to fibrosis stages F2 to F3, and is prescribed in combination with diet and exercise.

Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist and is structurally related to the endogenous thyroid hormone triiodothyronine (T3). By selectively activating THR-β receptors in the liver, resmetirom helps regulate lipid metabolism, reduce hepatic fat accumulation, and improve inflammatory and fibrotic processes associated with MASH. Its liver-targeted mechanism allows therapeutic benefits while minimizing systemic thyroid-related effects.

The drug represents a significant advancement in the management of MASH, a progressive fatty liver disease that can lead to cirrhosis, liver failure, and increased cardiovascular risk if left untreated. As the first FDA-approved oral therapy specifically targeting the underlying metabolic drivers of MASH, resmetirom offers a disease-modifying approach rather than symptomatic relief alone, making it a valuable option in modern hepatology treatment strategies.